A randomized controlled trial of a wearable technology-based intervention for increasing moderate to vigorous physical activity and reducing sedentary behavior in breast cancer survivors: The ACTIVATE Trial
A randomized controlled trial of a wearable technology-based intervention for increasing moderate to vigorous physical activity and reducing sedentary behavior in breast cancer survivors: The ACTIVATE Trial
复制标题
DOI：
10.1002/cncr.32143
复制
发表时间：
2019-08-15
期刊：
影响因子：
6.2
通讯作者：
English, Dallas R.
中科院分区：
文献类型：
--
作者：
Lynch, Brigid M.;Nguyen, Nga H.;English, Dallas R.
乳腺癌诊断后积极的生活方式的好处是公认的，但大多数幸存者都不够活跃。ACTIVATE试验检查了干预措施（使用Garmin Vivofit 2活动监测器，结合行为反馈和目标设定会议以及5次电话健康指导会议）的有效性，以增加中度到剧烈的体力活动（MVPA）并减少乳腺癌幸存者的久坐行为。方法本随机对照试验招募了83名已完成初步治疗的绝经后I-III期乳腺癌患者。参与者被随机分配到干预组或对照组，并在12周内进行干预。在基线（T1）和干预结束时（T2），使用Actigraph和activPAL加速度计测量MVPA和久坐行为。结果试验中的保留率很高，80（96%）名参与者完成了T2数据收集。T2时，MVPA组间差异显著（69 min/wk; 95% CI = 22-116），有利于干预组。该试验导致总坐位时间和坐位延长（>= 20 min）均出现统计学显著性减少，组间分别减少37 min/d（95% CI = -72至-2）和42 min/d（95% CI = -83至-2），有利于干预组。ACTIVATE试验的结果表明，可穿戴技术的使用提供了一个廉价且可扩展的机会，可以促进癌症幸存者更积极的生活方式。这种基于可穿戴技术的干预措施是否可以创造可持续的行为改变应该是未来研究的主题。
Background The benefits of an active lifestyle after a breast cancer diagnosis are well recognized, but the majority of survivors are insufficiently active. The ACTIVATE Trial examined the efficacy of an intervention (use of the Garmin Vivofit 2 activity monitor coupled with a behavioral feedback and goal-setting session and 5 telephone-delivered health coaching sessions) to increase moderate to vigorous physical activity (MVPA) and reduce sedentary behavior in breast cancer survivors. Methods This randomized controlled trial recruited 83 inactive, postmenopausal women diagnosed with stage I-III breast cancer who had completed primary treatment. Participants were randomly assigned to the intervention group or to the control group, and the intervention was delivered over a 12-week period. MVPA and sedentary behavior were measured with Actigraph and activPAL accelerometers at baseline (T1) and at the end of the intervention (T2). Results Retention in the trial was high, with 80 (96%) of participants completing T2 data collection. At T2, there was a significant between-group difference in MVPA (69 min/wk; 95% CI = 22-116) favoring the intervention group. The trial resulted in a statistically significant decrease in both total sitting time and prolonged bouts (>= 20 min) of sitting, with between-group reductions of 37 min/d (95% CI = -72 to -2) and 42 min/d (95% CI = -83 to -2), respectively, favoring the intervention group. Conclusion Results from the ACTIVATE Trial suggest that the use of wearable technology presents an inexpensive and scalable opportunity to facilitate more active lifestyles for cancer survivors. Whether or not such wearable technology-based interventions can create sustainable behavioral change should be the subject of future research.